Wegovy 4 mg Tablets – Semaglutide Medical Information
Wegovy 4 mg Overview
Wegovy 4 mg is an oral tablet formulation containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It represents the second strength in the oral Wegovy dose-escalation schedule for eligible adults receiving prescription weight-management treatment.
Semaglutide works by activating GLP-1 receptors involved in appetite regulation, food intake and glucose metabolism. Its effects on hunger and feelings of fullness contribute to its role in chronic weight-management treatment.
The 4 mg tablet follows the initial 1.5 mg strength in the published oral dosing schedule. Gradual dose escalation allows healthcare professionals to assess treatment tolerability before considering further increases to 9 mg and eventually 25 mg.
In Australia, Wegovy 4 mg tablets were registered by the Therapeutic Goods Administration (TGA) on 3 November 2026 under ARTG number 522757. Registration does not necessarily mean the product is immediately commercially available.
Wegovy 4 mg Product Information
| Product characteristic | Details |
|---|---|
| Brand name | Wegovy |
| Active ingredient | Semaglutide |
| Strength | 4 mg |
| Dosage form | Oral tablet |
| Administration | Oral |
| Frequency | Once daily |
| Drug class | GLP-1 receptor agonist |
| Treatment stage | Second dose-escalation stage |
| Manufacturer | Novo Nordisk |
| Australian registration | ARTG 522757 |
| Medicine classification | Prescription-only medicine |
What Is Semaglutide?
Semaglutide is a medication that mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in appetite regulation and glucose metabolism.
It activates GLP-1 receptors that influence several physiological processes, including hunger signals, feelings of fullness, gastric emptying and glucose-dependent insulin secretion.
Semaglutide is used in prescription treatments for certain metabolic conditions and chronic weight management. Its effects on appetite and food intake are particularly relevant to its use in obesity treatment.
How Does Wegovy 4 mg tablets Work?
Wegovy 4 mg works through the activity of semaglutide on GLP-1 receptors.
After absorption, semaglutide influences appetite-related pathways and helps regulate food intake. Its effects can include:
- Appetite regulation: Influences the signals associated with hunger and food consumption.
- Increased satiety: Helps increase feelings of fullness after meals.
- Gastric emptying: Influences the rate at which food moves from the stomach into the small intestine.
- Glucose regulation: Supports glucose-dependent insulin secretion and contributes to blood glucose regulation.
These mechanisms help explain how semaglutide can support weight-management treatment when combined with appropriate nutritional and physical activity interventions.
Individual responses vary, and treatment should be monitored by a qualified healthcare professional.
Why Is 4 mg the Second Strength?
The 4 mg tablet is the second stage in the oral Wegovy dose-escalation schedule.
Following the initial 1.5 mg treatment period, the dose increases to 4 mg as part of the gradual introduction of semaglutide.
This staged approach is intended to help the body adjust to treatment and reduce the likelihood of gastrointestinal adverse reactions associated with dose increases.
The 4 mg strength is not the standard maintenance strength in the published oral dosing schedule. It is an intermediate treatment stage before the 9 mg and 25 mg strengths.
Wegovy Oral Tablet Dosage Schedule
The published oral semaglutide dosing schedule involves four tablet strengths.
| Treatment period | Daily strength | Treatment stage |
|---|---|---|
| Days 1–30 | 1.5 mg | Initial stage |
| Days 31–60 | 4 mg | Second stage |
| Days 61–90 | 9 mg | Third stage |
| Day 91 onwards | 25 mg | Maintenance stage |
Each stage generally lasts at least 30 days. The prescribing healthcare professional determines whether dose escalation is appropriate based on tolerability and individual treatment circumstances.
Patients should not independently increase their dosage or combine different tablet strengths to achieve a higher dose.
How to Take Oral Wegovy 4 mg Tablets
Oral semaglutide has specific administration requirements because food, beverages and other oral medicines can influence absorption.
The published administration instructions include:
- Take the tablet in the morning after an overnight fast of at least eight hours.
- Swallow the tablet whole with plain water.
- Use no more than 120 mL of water.
- Do not crush, chew, split or dissolve the tablet.
- Wait at least 30 minutes before eating, drinking or taking other oral medicines.
Following these instructions is important for consistent medication absorption.
Patients should follow the current Australian-approved Product Information and instructions provided by their prescriber or pharmacist.
Possible Side Effects of Wegovy 4 mg tablet
Like other semaglutide-containing medicines, Wegovy may cause adverse reactions.
Gastrointestinal effects are among the commonly reported reactions, particularly during treatment initiation and dose escalation.
Potential side effects include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort
- Bloating
- Indigestion
- Reduced appetite
Some symptoms may improve as the body adjusts to treatment. However, persistent or severe symptoms should be discussed with a healthcare professional.
More serious potential risks include pancreatitis, gallbladder disease, dehydration-related kidney problems and serious allergic reactions.
Severe or persistent abdominal pain, especially when accompanied by vomiting, requires urgent medical assessment.
Warnings and Precautions
Before starting or continuing semaglutide treatment, patients should discuss their medical history with their healthcare professional.
Important considerations include:
- Previous pancreatitis.
- Gallbladder disease or gallstones.
- Kidney problems.
- Diabetes and medicines that may cause hypoglycaemia.
- Severe gastrointestinal conditions.
- Pregnancy or plans for pregnancy.
- Breastfeeding.
- Previous allergic reactions to semaglutide or formulation ingredients.
Semaglutide should not be used for weight reduction during pregnancy. Patients planning pregnancy should discuss the appropriate discontinuation period with their healthcare professional.
The current approved Product Information should be consulted for the complete contraindications, warnings and precautions.
Wegovy 4 mg tablets Drug Interactions
Semaglutide may affect the absorption of certain oral medicines because it can delay gastric emptying.
Patients should inform their healthcare professional about all medicines they use, including prescription treatments, non-prescription medicines, vitamins and supplements.
Additional monitoring may be necessary when semaglutide is used alongside certain diabetes medicines or medicines requiring close therapeutic monitoring.
Combining Wegovy with other semaglutide-containing products or GLP-1 receptor agonists is generally not recommended unless specifically directed by an appropriate healthcare professional.
Wegovy 4 mg tablets vs Wegovy Injection
Oral Wegovy and injectable Wegovy contain the same active ingredient, semaglutide, but have different administration methods and dosing schedules.
| Characteristic | Oral Wegovy | Injectable Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Administration | Oral tablet | Subcutaneous injection |
| Frequency | Once daily | Once weekly |
| 4 mg tablet | Second oral dose-escalation strength | Not an equivalent injection dose |
| Maintenance strength | 25 mg daily | Depends on the approved injectable regimen |
The strengths of oral and injectable semaglutide are not directly interchangeable because their absorption characteristics differ.
Patients should not independently switch formulations or calculate equivalent doses.
Wegovy 4 mg tablets in Australia
Wegovy 4 mg tablets were registered in the Australian Register of Therapeutic Goods on 3 November 2026.
Australian registration information:
- Product: Wegovy semaglutide 4 mg tablet blister pack
- ARTG number: 522757
- Active ingredient: Semaglutide
- Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd
- Registration date: 3 November 2026
- Medicine classification: Prescription medicine
TGA registration establishes the medicine’s regulatory registration status. It should not be confused with immediate commercial availability, pharmacy stock or PBS subsidy.
Australian patients and healthcare professionals should consult the TGA and the manufacturer for current supply information and approved product documentation.
Storage and Handling
Wegovy tablets should be stored according to the conditions specified in the approved product packaging and Consumer Medicine Information.
Keep medicines away from children and do not use tablets beyond their expiry date.
For specific storage temperatures, packaging requirements and handling instructions, consult the current product documentation.
Frequently Asked Questions About Wegovy 4 mg tablets
What is Wegovy 4 mg tablets used for?
Wegovy 4 mg is the second strength in the oral semaglutide dose-escalation schedule. It follows the initial 1.5 mg stage and precedes the 9 mg and 25 mg strengths.
Is Wegovy 4 mg a daily tablet?
Yes. The oral formulation is designed for once-daily administration, following specific fasting and water requirements.
How long is Wegovy 4 mg tablets taken?
The standard dose-escalation schedule uses the 4 mg strength for at least 30 days. Treatment progression depends on individual tolerability and the prescribing healthcare professional’s assessment.
What comes after Wegovy 4 mg tablets?
The published oral dosing schedule progresses to 9 mg, followed by the 25 mg maintenance strength.
Is Wegovy 4 mg tablets a maintenance dose?
No. The 4 mg tablet is an intermediate dose-escalation strength. The standard oral maintenance strength is 25 mg once daily.
Can Wegovy 4 mg tablets be taken with food?
The oral formulation should be taken after an overnight fast with plain water. Patients should wait at least 30 minutes before eating, drinking or taking other oral medicines.
Is Wegovy 4 mg the same as a 4 mg injection?
No. The 4 mg oral tablet is not equivalent to a 4 mg injectable dose. Oral and injectable semaglutide have different absorption characteristics and dosing schedules.
Is Wegovy 4 mg tablets approved in Australia?
Yes. The TGA registered the 4 mg oral tablet formulation on 3 November 2026 under ARTG number 522757. Commercial availability is a separate matter.
Does Wegovy 4 mg tablets guarantee weight loss?
No. Individual responses to semaglutide vary. Treatment should be considered as part of a comprehensive weight-management programme under medical supervision.
Medical Disclaimer
This information is provided for general educational purposes only. It does not replace professional medical advice, diagnosis or treatment.
Wegovy is a prescription medicine. Patients should consult a qualified Australian healthcare professional before starting, changing or stopping any medication.
Medical information should be checked against the latest Australian-approved Product Information and Consumer Medicine Information before publication.
Important regulatory consideration: Prescription-only medicines have strict advertising restrictions in Australia under the Therapeutic Goods Act and TGA advertising requirements. Public-facing promotion of prescription-only Wegovy, including product-specific promotional descriptions, calls to purchase and testimonials, can be problematic. Keep these pages educational and non-promotional, and obtain Australian regulatory review before publishing commercial product listings.
Useful references:
Reviews
There are no reviews yet.